中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (9): 849-852.doi: 10.35541/cjd.20220317

• 研究报道 • 上一篇    下一篇

JAK抑制剂治疗儿童重症斑秃5例

刘元香    梁源    赵欣荣    孙玉娟    马琳    徐子刚   

  1. 国家儿童医学中心  首都医科大学附属北京儿童医院皮肤科,北京  100045
  • 收稿日期:2022-05-05 修回日期:2023-02-28 发布日期:2023-09-07
  • 通讯作者: 徐子刚 E-mail:zigangxupek@163.com
  • 基金资助:
    北京市自然科学基金

Janus kinase inhibitors for the treatment of five children with severe alopecia areata

Liu Yuanxiang, Liang Yuan, Zhao Xinrong, Sun Yujuan, Ma Lin, Xu Zigang   

  1. Department of Dermatology, Beijing Children′s Hospital, Capital Medical University, National Center for Children′s Health, China, Beijing 100045, China
  • Received:2022-05-05 Revised:2023-02-28 Published:2023-09-07
  • Contact: Xu Zigang E-mail:zigangxupek@163.com
  • Supported by:
    Natural Science Foundation of Beijing Municipality

摘要: 【摘要】 目的 观察JAK抑制剂治疗5例儿童重症斑秃及合并甲改变患者的疗效。方法 收集2020年1月至2022年4月于北京儿童医院就诊的5例重症斑秃患儿,予JAK抑制剂(托法替布或巴瑞替尼)口服治疗,采用斑秃严重程度评估工具(SALT)评估治疗12、24、36、48周秃发改善程度。对其中3例合并甲改变的重症斑秃患儿,采用改良的甲银屑病指数评分评估治疗前后甲病的改善程度。治疗过程中同时监测不良反应。结果 5例重症斑秃患儿,年龄2 ~ 11岁,病程5 ~ 120个月,JAK抑制剂疗程24 ~ 48周。治疗12周,2例患儿SALT改善率达SALT50;治疗24周,3例达SALT95,1例达SALT75后自行停药;治疗36周,3例达SALT99,开始减半量治疗;治疗48周,4例SALT改善率分别为SALT99、SALT83、SALT31、SALT0,其中2例为减半量治疗1 ~ 2个月出现反复并逐渐加重。3例合并甲改变的患儿,治疗12周后手指甲严重程度指数改善率分别为67.5%、45.4%和25%,足趾甲分别为42.5%、71.4%和5%;治疗48周,这3例手指甲改善率分别为100%、100%、50%,足趾甲分别为96.2%、100%、50%。治疗过程中,2例患儿尿酸升高,其中1例同时合并血低密度脂蛋白胆固醇和高密度脂蛋白胆固醇水平升高;1例治疗期间发生2次呼吸道感染,对症治疗后恢复,均未影响治疗。结论 JAK抑制剂可作为儿童重症斑秃的治疗选择。

关键词: 斑秃, 指(趾)甲, JAK抑制剂, 治疗结果, 儿童

Abstract: 【Abstract】 Objective To evaluate the efficacy of Janus kinase (JAK) inhibitors in the treatment of 5 children with severe alopecia areata, especially those with complicated nail damage. Methods A total of 5 children with severe alopecia areata were enrolled and treated with oral JAK inhibitors (tofacitinib or baricitinib). The improvement of hair loss was assessed by using the severity of alopecia tool (SALT) at 12, 24, 36, and 48 weeks after the start of treatment. For 3 children with complicated nail damage, the improvement of diseased nails and toenails was evaluated by using the modified nail psoriasis severity index after treatment. During the treatment, adverse reactions were monitored. Results The five children with severe alopecia areata were aged 2 - 11 years, their disease duration ranged from 5 to 120 months, and the treatment with JAK inhibitors lasted 24 - 48 weeks. After 12-week treatment, 2 children achieved a 50% improvement in SALT (SALT50); after 24-week treatment, 3 achieved SALT95, and 1 achieved SALT75 and then withdrew baricitinib for personal reasons; after 36-week treatment, 3 achieved SALT99, and then received half-dose treatment; after 48-week treatment, 1, 1, 1 and 1 patient achieved SALT99, SALT83, SALT31, and SALT0, respectively, and 2 of them experienced gradually aggravated hair loss 1 - 2 months after the half-dose treatment. Among the 3 children with complicated nail damage, the improvement rates of nail severity index scores were 67.5%, 45.4%, and 25% respectively, and the improvement rates of toenail severity index scores were 42.5%, 71.4%, and 5% respectively after 12-week treatment; after 48-week treatment, the improvement rate of nail severity index scores were 100%, 100%, and 50% respectively, and the improvement rate of toenail severity index scores were 96.2%, 100%, 50% respectively. During the treatment, the uric acid level increased in 2 children, and one of them was accompanied by increased serum levels of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol; 1 suffered from respiratory tract infections twice during the treatment, and was recovered after symptomatic treatment; there were no adverse reactions leading to drug withdrawal. Conclusion JAK inhibitors can be used as a treatment option for severe alopecia areata in children.

Key words: Alopecia areata, Nails, JAK inhibitors, Treatment outcome, Child

引用本文

刘元香 梁源 赵欣荣 孙玉娟 马琳 徐子刚. JAK抑制剂治疗儿童重症斑秃5例[J]. 中华皮肤科杂志, 2023,56(9):849-852. doi:10.35541/cjd.20220317

Liu Yuanxiang, Liang Yuan, Zhao Xinrong, Sun Yujuan, Ma Lin, Xu Zigang. Janus kinase inhibitors for the treatment of five children with severe alopecia areata[J]. Chinese Journal of Dermatology, 2023, 56(9): 849-852.doi:10.35541/cjd.20220317